Elsa Lestang

Nantes, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-A FIM study.

Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-A FIM study.

Journal: HemaSphere

Published: March 17, 2025

Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: real-world data from the EarlyMIND study.

Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: real-world data from the EarlyMIND study.

Journal: Haematologica

Published: December 10, 2024

Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.

Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.

Journal: Haematologica

Published: November 12, 2019

CD200 expression in flow cytometry helps to distinguish mantle cell lymphoma from other CD5-positive B-cell neoplasms.

CD200 expression in flow cytometry helps to distinguish mantle cell lymphoma from other CD5-positive B-cell neoplasms.

Journal: Hematological oncology

Published: January 05, 2018

Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?

Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?

Journal: European journal of haematology

Published: March 27, 2017

Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study.

Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 06, 2015

Control of Pim2 kinase stability and expression in transformed human haematopoietic cells.

Control of Pim2 kinase stability and expression in transformed human haematopoietic cells.

Journal: Bioscience reports

Published: August 19, 2015

Lenalidomide as frontline therapy in polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes syndrome: a retrospective case series of eight patients.

Lenalidomide as frontline therapy in polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes syndrome: a retrospective case series of eight patients.

Journal: Leukemia & lymphoma

Published: October 28, 2014

18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study.

18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study.

Journal: Bone marrow transplantation

Published: April 22, 2013

Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).

Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).

Journal: European journal of haematology

Published: November 28, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026